VOR Vor Biopharma Inc

Price (delayed)

$0.925

Market cap

$63.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.77

Enterprise value

$50.5M

Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that ...

Highlights
VOR's EPS is up by 18% YoY
The debt is down by 10% YoY and by 2.6% from the previous quarter
Vor Biopharma's quick ratio has plunged by 51% YoY and by 7% from the previous quarter
Vor Biopharma's equity has decreased by 47% YoY and by 18% from the previous quarter

Key stats

What are the main financial stats of VOR
Market
Shares outstanding
68.26M
Market cap
$63.14M
Enterprise value
$50.5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$120.23M
EBITDA
-$112.63M
Free cash flow
-$107.58M
Per share
EPS
-$1.77
Free cash flow per share
-$1.58
Book value per share
$1.8
Revenue per share
$0
TBVPS
$2.46
Balance sheet
Total assets
$167.03M
Total liabilities
$44M
Debt
$34.74M
Equity
$123.04M
Working capital
$98.6M
Liquidity
Debt to equity
0.28
Current ratio
8.46
Quick ratio
8.32
Net debt/EBITDA
0.11
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-57.3%
Return on equity
-73.7%
Return on invested capital
-63%
Return on capital employed
-78.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VOR stock price

How has the Vor Biopharma stock price performed over time
Intraday
0.54%
1 week
-4.64%
1 month
-22.27%
1 year
-72.39%
YTD
-58.89%
QTD
-7.5%

Financial performance

How have Vor Biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$127.94M
Net income
-$120.23M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 27% YoY
The net income has contracted by 23% YoY and by 2% from the previous quarter

Growth

What is Vor Biopharma's growth rate over time

Valuation

What is Vor Biopharma stock price valuation
P/E
N/A
P/B
0.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
VOR's EPS is up by 18% YoY
VOR's price to book (P/B) is 49% less than its last 4 quarters average of 1.0
Vor Biopharma's equity has decreased by 47% YoY and by 18% from the previous quarter

Efficiency

How efficient is Vor Biopharma business performance
The company's return on equity has shrunk by 54% YoY and by 19% QoQ
The return on assets has declined by 48% year-on-year and by 16% since the previous quarter
The return on invested capital has declined by 43% year-on-year and by 18% since the previous quarter

Dividends

What is VOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VOR.

Financial health

How did Vor Biopharma financials performed over time
Vor Biopharma's current ratio has plunged by 51% YoY and by 6% from the previous quarter
Vor Biopharma's quick ratio has plunged by 51% YoY and by 7% from the previous quarter
The debt is 72% less than the equity
Vor Biopharma's debt to equity has surged by 65% YoY and by 17% QoQ
Vor Biopharma's equity has decreased by 47% YoY and by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.